• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine.了解阿塞那平的口腔黏膜吸收及其临床药代动力学结果。
AAPS PharmSciTech. 2012 Dec;13(4):1110-5. doi: 10.1208/s12249-012-9839-7. Epub 2012 Aug 31.
2
Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects.舌下给予阿散平后吸收部位对健康男性受试者药代动力学的影响。
Biopharm Drug Dispos. 2010 Jul;31(5-6):351-7. doi: 10.1002/bdd.718.
3
[Analysis of factors governing drug absorption and their improvement].[药物吸收的影响因素及其改善分析]
Yakugaku Zasshi. 2009 Aug;129(8):911-23. doi: 10.1248/yakushi.129.911.
4
The effect of food on the high clearance drug asenapine after sublingual administration to healthy male volunteers.食物对健康男性志愿者舌下给药后高清除率药物阿立哌唑的影响。 需注意,你原文中的药物名称可能有误,文本中说的是阿立哌唑(Aripiprazole),而不是阿塞那平(Asenapine),我按照纠正后的药物名称翻译,以免造成误解。若有特殊要求,请根据实际情况调整。
Eur J Clin Pharmacol. 2015 Jan;71(1):65-74. doi: 10.1007/s00228-013-1587-4. Epub 2015 Jan 1.
5
Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations.丙戊酸可降低阿塞那平的葡萄糖醛酸化,而不影响阿塞那平的血浆浓度。
J Clin Pharmacol. 2012 May;52(5):757-65. doi: 10.1177/0091270011404028. Epub 2011 May 31.
6
Preferential Formulation of Second Generation Antipsychotic Asenapine as Inclusion Complex with Sulphobutylether-βCD (Captisol): In vitro and In vivo Evaluation.第二代抗精神病药物阿塞那平与磺丁基醚-β环糊精(Captisol)形成包合物的优选制剂:体内外评价
Curr Drug Deliv. 2018;15(4):520-531. doi: 10.2174/1567201814666171120121217.
7
Self-emulsifying drug delivery system for enhanced solubility of asenapine maleate: design, characterization, in vitro, ex vivo and in vivo appraisal.马来酸阿塞那平自乳化给药系统提高其溶解度的研究:设计、表征、体外、离体和体内评价。
Drug Dev Ind Pharm. 2019 Apr;45(4):548-559. doi: 10.1080/03639045.2019.1567758. Epub 2019 Feb 3.
8
Asenapine pharmacokinetics in hepatic and renal impairment.阿塞那平在肝肾功能损害患者中的药代动力学。
Clin Pharmacokinet. 2011 Jul;50(7):471-81. doi: 10.2165/11590490-000000000-00000.
9
Novel Drug Delivery Approach via Self-Microemulsifying Drug Delivery System for Enhancing Oral Bioavailability of Asenapine Maleate: Optimization, Characterization, Cell Uptake, and In Vivo Pharmacokinetic Studies.马来酸阿散平经自微乳药物传递系统给药提高口服生物利用度的新型给药方法:优化、表征、细胞摄取及体内药代动力学研究。
AAPS PharmSciTech. 2019 Jan 7;20(2):44. doi: 10.1208/s12249-018-1212-z.
10
Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.口腔黏膜给药:临床药代动力学与治疗应用。
Clin Pharmacokinet. 2002;41(9):661-80. doi: 10.2165/00003088-200241090-00003.

引用本文的文献

1
In Vitro Oral Cavity Permeability Assessment to Enable Simulation of Drug Absorption.体外口腔通透性评估以实现药物吸收模拟
Pharmaceutics. 2025 Jul 17;17(7):924. doi: 10.3390/pharmaceutics17070924.
2
Evaluation of Drug Permeation Enhancement by Using In Vitro and Ex Vivo Models.使用体外和离体模型评估药物渗透增强作用
Pharmaceuticals (Basel). 2025 Jan 31;18(2):195. doi: 10.3390/ph18020195.
3
In vitro and ex vivo models of the oral mucosa as platforms for the validation of novel drug delivery systems.作为新型药物递送系统验证平台的口腔黏膜体外和离体模型。
J Tissue Eng. 2025 Feb 11;16:20417314241313458. doi: 10.1177/20417314241313458. eCollection 2025 Jan-Dec.
4
Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma.新辅助 toll 样受体 7 激动剂(咪喹莫特)免疫疗法在早期口腔鳞状细胞癌中的临床试验
Front Immunol. 2025 Jan 27;16:1530262. doi: 10.3389/fimmu.2025.1530262. eCollection 2025.
5
Therapeutic Impact of Ascorbic Acid on Oral and Periodontal Tissues: A Systematic Literature Review.抗坏血酸对口腔及牙周组织的治疗作用:一项系统文献综述
Medicina (Kaunas). 2024 Dec 11;60(12):2041. doi: 10.3390/medicina60122041.
6
Eradication of proliferative verrucous leukoplakia with toll-like receptor 7 agonist (topical imiquimod): a case report.使用Toll样受体7激动剂(局部咪喹莫特)根除增殖性疣状白斑:一例报告
Front Oncol. 2024 Nov 15;14:1473889. doi: 10.3389/fonc.2024.1473889. eCollection 2024.
7
Evaluation of Monolayer and Bilayer Buccal Films Containing Metoclopramide.含胃复安的单层和双层口腔膜片的评估。
Pharmaceutics. 2024 Mar 2;16(3):354. doi: 10.3390/pharmaceutics16030354.
8
The Bioavailability of CHF6563, an Ethanol-Free, Sublingual Neonatal Buprenorphine Formulation: A Bridging Study Conducted in Adults.CHF6563(一种不含乙醇的舌下含服新生儿丁丙诺啡制剂)的生物利用度:一项在成人中开展的桥接研究。
J Pediatr Pharmacol Ther. 2024;29(1):49-52. doi: 10.5863/1551-6776-29.1.49. Epub 2024 Feb 7.
9
Reduced Use of Antibiotics and Nasal Decongestants During Treatment with a Mouthwash Containing Delmopinol.使用含有地洛哌丁醇的漱口水治疗期间减少抗生素和鼻减充血剂的使用。
Oral Health Prev Dent. 2023 Nov 2;21:347-356. doi: 10.3290/j.ohpd.b4586769.
10
The Extraordinary Case of a Woman with a 30-Year-Long Diffuse Leishmaniasis Cured with One Single Ampoule of Intranasal Pentavalent Antimoniate.一位患有长达30年弥漫性利什曼病的女性仅通过一剂鼻内注射五价锑酸盐就得以治愈的非凡病例。
Pathogens. 2023 Jun 29;12(7):890. doi: 10.3390/pathogens12070890.

本文引用的文献

1
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.阿塞那平:一种具有独特人类受体特征的新型精神药理学药物。
J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28.
2
Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.在纳曲酮阻滞下,阿片类药物初治的健康男性志愿者单次舌下含服高剂量丁丙诺啡片剂后的药代动力学。
Drug Alcohol Depend. 2003 Oct 24;72(1):75-83. doi: 10.1016/s0376-8716(03)00188-1.
3
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.杂环药物的Caco-2通透性、P-糖蛋白转运率及脑内渗透率
Int J Pharm. 2003 Sep 16;263(1-2):113-22. doi: 10.1016/s0378-5173(03)00372-7.
4
Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.口腔黏膜给药:临床药代动力学与治疗应用。
Clin Pharmacokinet. 2002;41(9):661-80. doi: 10.2165/00003088-200241090-00003.
5
Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation.维拉帕米及其代谢产物去甲维拉帕米经口腔给药制剂的药代动力学。
Int J Pharm. 2002 May 15;238(1-2):181-9. doi: 10.1016/s0378-5173(02)00069-8.
6
Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans.健康人体中单次口服负荷剂量普罗帕酮的口腔吸收动力学。
Gen Pharmacol. 1998 Oct;31(4):589-91. doi: 10.1016/s0306-3623(98)00045-7.
7
Clinical pharmacokinetics of vasodilators. Part II.血管扩张剂的临床药代动力学。第二部分。
Clin Pharmacokinet. 1998 Jul;35(1):9-36. doi: 10.2165/00003088-199835010-00002.
8
Studies on the bioavailability of glyceryl trinitrate after sublingual administration of spray and tablet.舌下喷雾和舌下片剂给药后硝酸甘油生物利用度的研究。
Arzneimittelforschung. 1997 Jun;47(6):716-8.
9
A pharmacokinetic study of sublingual aerosolized morphine in healthy volunteers.健康志愿者中舌下雾化吗啡的药代动力学研究。
J Pharm Pharmacol. 1996 Dec;48(12):1256-9. doi: 10.1111/j.2042-7158.1996.tb03932.x.
10
A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.阿扑吗啡的一种新型舌下制剂用于帕金森病患者的治疗。
Mov Disord. 1996 Nov;11(6):633-8. doi: 10.1002/mds.870110607.

了解阿塞那平的口腔黏膜吸收及其临床药代动力学结果。

Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine.

机构信息

Pharmaceutical Development, Worldwide Pharmaceutical Sciences, Pfizer Global Research and Development, Groton, Connecticut 06340, USA.

出版信息

AAPS PharmSciTech. 2012 Dec;13(4):1110-5. doi: 10.1208/s12249-012-9839-7. Epub 2012 Aug 31.

DOI:10.1208/s12249-012-9839-7
PMID:22936407
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3513449/
Abstract

Absorption of drugs from the oral cavity into the mucosal tissues is typically a fast event. Dissolved drugs partition into the mucosal membranes and within minutes will reach equilibrium with drug in solution in the oral cavity. However, this does not always equate to rapid drug appearance in the systemic circulation. This has been attributed to slow partitioning out of the mucosal tissues and into the systemic circulation. Based on information from literature, physicochemical properties of asenapine, and clinical data, we conclude that for sublingually administered asenapine, the exposure is primarily a function of rapid partitioning into the mucosal membranes. This is followed by slow partitioning out of the mucosal tissues and into the systemic circulation, leading to a T (max) value of about 1 h. The bioavailability of asenapine at doses below the saturation solubility in the mouth does not change and is controlled primarily by mass transport equilibrium. At doses above the saturation solubility, the bioavailability becomes more dependent not only on the distribution equilibrium but also on contact time in the mouth because additional variables (e.g. dissolution rate of the drug) need to be accounted for. These explanations are consistent with oral cavity absorption models from the literature and can be used to accurately describe the clinical data for asenapine.

摘要

药物从口腔进入黏膜组织的吸收通常是一个快速的过程。溶解的药物分配到黏膜中,几分钟内就会与口腔中药物的溶液达到平衡。然而,这并不总是等同于药物迅速出现在全身循环中。这归因于药物从黏膜组织缓慢分配到全身循环中。根据文献中的信息、阿塞纳平的物理化学性质和临床数据,我们得出结论,对于舌下给予的阿塞纳平,其暴露主要是快速分配到黏膜中的结果。然后,药物从黏膜组织缓慢分配到全身循环中,导致 T(max)值约为 1 小时。在口腔中饱和溶解度以下的剂量下,阿塞纳平的生物利用度不会改变,主要受质量传递平衡控制。在高于饱和溶解度的剂量下,生物利用度不仅取决于分布平衡,还取决于在口腔中的接触时间,因为需要考虑其他变量(例如药物的溶解速率)。这些解释与文献中的口腔吸收模型一致,可用于准确描述阿塞纳平的临床数据。